Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Rockwell Med ( (RMTI) ) is now available.
On December 31, 2025, Rockwell Medical, Inc. and DaVita, Inc. entered into a second amendment to their existing products purchase agreement, extending its term by one year to December 31, 2026, effective as of December 23, 2025. The amendment also introduces a price increase on products sold during the extended term, which is likely to support Rockwell Medical’s revenue profile while reinforcing its commercial relationship with a key dialysis provider customer, with implications for contract stability and pricing power in its core market.
The most recent analyst rating on (RMTI) stock is a Hold with a $0.88 price target. To see the full list of analyst forecasts on Rockwell Med stock, see the RMTI Stock Forecast page.
Spark’s Take on RMTI Stock
According to Spark, TipRanks’ AI Analyst, RMTI is a Neutral.
Rockwell Med’s overall stock score is primarily impacted by its weak financial performance and valuation. The technical analysis indicates bearish momentum, further weighing down the score. While the earnings call and corporate events provide some positive insights, they are not sufficient to offset the significant financial and valuation challenges.
To see Spark’s full report on RMTI stock, click here.
More about Rockwell Med
Rockwell Medical, Inc. operates in the healthcare sector, supplying medical products used in dialysis and related therapies under long-term purchase agreements with major providers such as DaVita, Inc.
Average Trading Volume: 359,636
Technical Sentiment Signal: Sell
Current Market Cap: $34.02M
Find detailed analytics on RMTI stock on TipRanks’ Stock Analysis page.